CDGSH iron sulfur domain 2 can inhibit ferroptosis,which has been associated with cerebral ischemia/reperfusion,in individuals with head and neck cancer.Therefore,CDGSH iron sulfur domain 2 may be implicated in cerebr...CDGSH iron sulfur domain 2 can inhibit ferroptosis,which has been associated with cerebral ischemia/reperfusion,in individuals with head and neck cancer.Therefore,CDGSH iron sulfur domain 2 may be implicated in cerebral ischemia/reperfusion injury.To validate this hypothesis in the present study,we established mouse models of occlusion of the middle cerebral artery and HT22 cell models of oxygen-glucose deprivation and reoxygenation to mimic cerebral ischemia/reperfusion injury in vivo and in vitro,respectively.We found remarkably decreased CDGSH iron sulfur domain 2 expression in the mouse brain tissue and HT22 cells.When we used adeno-associated virus and plasmid to up-regulate CDGSH iron sulfur domain 2 expression in the brain tissue and HT22 cell models separately,mouse neurological dysfunction was greatly improved;the cerebral infarct volume was reduced;the survival rate of HT22 cells was increased;HT22 cell injury was alleviated;the expression of ferroptosis-related glutathione peroxidase 4,cystine-glutamate antiporter,and glutathione was increased;the levels of malondialdehyde,iron ions,and the expression of transferrin receptor 1 were decreased;and the expression of nuclear-factor E2-related factor 2/heme oxygenase 1 was increased.Inhibition of CDGSH iron sulfur domain 2 upregulation via the nuclear-factor E2-related factor 2 inhibitor ML385 in oxygen-glucose deprived and reoxygenated HT22 cells blocked the neuroprotective effects of CDGSH iron sulfur domain 2 up-regulation and the activation of the nuclear-factor E2-related factor 2/heme oxygenase 1 pathway.Our data indicate that the up-regulation of CDGSH iron sulfur domain 2 can attenuate cerebral ischemia/reperfusion injury,thus providing theoretical support from the perspectives of cytology and experimental zoology for the use of this protein as a therapeutic target in patients with cerebral ischemia/reperfusion injury.展开更多
目的探讨血清铁调节蛋白2(iron-regulated protein 2,IRP2)、诱饵受体3(decoy receptor 3,DcR3)水平与老年慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者疾病转归的关系。方法...目的探讨血清铁调节蛋白2(iron-regulated protein 2,IRP2)、诱饵受体3(decoy receptor 3,DcR3)水平与老年慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者疾病转归的关系。方法选择AECOPD患者(AECOPD组)88例,检测血清IRP2、DcR3水平,追踪AECOPD患者临床疾病转归,根据临床疾病转归将其分为恶化组(22例)和好转组(66例)。多因素Logistic回归分析AECOPD患者疾病转归的影响因素。受试者工作特征曲线(receiver operating characteristic curve,ROC)分析IRP2、DcR3预测AECOPD患者疾病转归的价值。结果恶化组近1年AECOPD发作次数、急性生理和慢性健康状况评分、合并休克、呼吸困难评分(modified medical research council,mMRC)分级3~4级高于好转组(P<0.05)。恶化组治疗前和治疗2周后血清IRP2、DcR3水平高于好转组,治疗2周后好转组血清IRP2、DcR3水平低于治疗前(P<0.05);恶化组血清IRP2、DcR3水平与治疗前比较差异无统计学意义(P>0.05)。多因素Logistic回归分析结果显示,近1年AECOPD发作次数、mMRC分级、治疗前IRP2、治疗前DcR3是AECOPD患者疾病恶化的危险因素(P<0.05)。治疗前IRP2、DcR3预测AECOPD患者疾病转归的曲线下面积为0.781、0.795,联合IRP2、DcR3预测AECOPD患者疾病转归的曲线下面积为0.918,大于单独IRP2、DcR3预测(P<0.05)。结论AECOPD患者血清IRP2、DcR3水平均显著增高,且与肺功能降低以及疾病恶化有关,检测血清IRP2、DcR3水平有助于对AECOPD患者疾病转归的预测。展开更多
基金supported by the National Natural Science Foundation of China,No.81402930Natural Science Foundation of Universities in Anhui Province,No.KJ2021A0688+2 种基金National College Students Innovation and Entrepreneurship Program,No.202110367071Key projects of science and technology projects of Bengbu Medical College,No.2020byzd017512 Talents Training Program of Bengbu Medical College,No.BY51201104(all to SYD).
文摘CDGSH iron sulfur domain 2 can inhibit ferroptosis,which has been associated with cerebral ischemia/reperfusion,in individuals with head and neck cancer.Therefore,CDGSH iron sulfur domain 2 may be implicated in cerebral ischemia/reperfusion injury.To validate this hypothesis in the present study,we established mouse models of occlusion of the middle cerebral artery and HT22 cell models of oxygen-glucose deprivation and reoxygenation to mimic cerebral ischemia/reperfusion injury in vivo and in vitro,respectively.We found remarkably decreased CDGSH iron sulfur domain 2 expression in the mouse brain tissue and HT22 cells.When we used adeno-associated virus and plasmid to up-regulate CDGSH iron sulfur domain 2 expression in the brain tissue and HT22 cell models separately,mouse neurological dysfunction was greatly improved;the cerebral infarct volume was reduced;the survival rate of HT22 cells was increased;HT22 cell injury was alleviated;the expression of ferroptosis-related glutathione peroxidase 4,cystine-glutamate antiporter,and glutathione was increased;the levels of malondialdehyde,iron ions,and the expression of transferrin receptor 1 were decreased;and the expression of nuclear-factor E2-related factor 2/heme oxygenase 1 was increased.Inhibition of CDGSH iron sulfur domain 2 upregulation via the nuclear-factor E2-related factor 2 inhibitor ML385 in oxygen-glucose deprived and reoxygenated HT22 cells blocked the neuroprotective effects of CDGSH iron sulfur domain 2 up-regulation and the activation of the nuclear-factor E2-related factor 2/heme oxygenase 1 pathway.Our data indicate that the up-regulation of CDGSH iron sulfur domain 2 can attenuate cerebral ischemia/reperfusion injury,thus providing theoretical support from the perspectives of cytology and experimental zoology for the use of this protein as a therapeutic target in patients with cerebral ischemia/reperfusion injury.
文摘目的探讨血清铁调节蛋白2(iron-regulated protein 2,IRP2)、诱饵受体3(decoy receptor 3,DcR3)水平与老年慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者疾病转归的关系。方法选择AECOPD患者(AECOPD组)88例,检测血清IRP2、DcR3水平,追踪AECOPD患者临床疾病转归,根据临床疾病转归将其分为恶化组(22例)和好转组(66例)。多因素Logistic回归分析AECOPD患者疾病转归的影响因素。受试者工作特征曲线(receiver operating characteristic curve,ROC)分析IRP2、DcR3预测AECOPD患者疾病转归的价值。结果恶化组近1年AECOPD发作次数、急性生理和慢性健康状况评分、合并休克、呼吸困难评分(modified medical research council,mMRC)分级3~4级高于好转组(P<0.05)。恶化组治疗前和治疗2周后血清IRP2、DcR3水平高于好转组,治疗2周后好转组血清IRP2、DcR3水平低于治疗前(P<0.05);恶化组血清IRP2、DcR3水平与治疗前比较差异无统计学意义(P>0.05)。多因素Logistic回归分析结果显示,近1年AECOPD发作次数、mMRC分级、治疗前IRP2、治疗前DcR3是AECOPD患者疾病恶化的危险因素(P<0.05)。治疗前IRP2、DcR3预测AECOPD患者疾病转归的曲线下面积为0.781、0.795,联合IRP2、DcR3预测AECOPD患者疾病转归的曲线下面积为0.918,大于单独IRP2、DcR3预测(P<0.05)。结论AECOPD患者血清IRP2、DcR3水平均显著增高,且与肺功能降低以及疾病恶化有关,检测血清IRP2、DcR3水平有助于对AECOPD患者疾病转归的预测。
